Free Republic 2nd Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $42,377
52%  
Woo hoo!! And we're now over 52%!! Thank you all very much!! God bless.

Keyword: reminyl

Brevity: Headers | « Text »
  • Alzheimer's drug may be poison antidote - study (maybe for nerve agents)

    08/07/2006 7:33:14 PM PDT · by neverdem · 5 replies · 462+ views
    Reuters ^ | Aug 7, 2006 | Maggie Fox
    Health and Science Correspondent WASHINGTON, Aug 7 (Reuters) - An Alzheimer's pill that helps slow the brain damage caused by the disease may also protect against the effects of nerve gases and pesticides, U.S. researchers reported on Monday. They said the drug, marketed under the name Reminyl and Razadyne, completely protected guinea pigs against the nerve agents soman and sarin, as well as toxic amounts of pesticides. They gave the animals high doses of the poisons and treated them with Reminyl, known generically as galantamine, along with atropine, often given as an antidote for organophospate pesticides such as paraoxon. "To...
  • Alzheimer's drug 'a poison antidote'

    08/07/2006 3:02:29 PM PDT · by WmShirerAdmirer · 6 replies · 572+ views
    The Australian ^ | August 8, 2006 | Australian correspondents in Washington
    An Alzheimer's pill that helps slow the brain damage caused by the disease may also protect against the effects of nerve gases and pesticides, US researchers reported today. They said the drug, marketed under the name Reminyl and Razadyne, completely protected guinea pigs against the nerve agents soman and sarin, as well as toxic amounts of pesticides. They gave the animals high doses of the poisons and treated them with Reminyl, known generically as galantamine, along with atropine, often given as an antidote for organophosphate pesticides such as paraoxon. "To our amazement, the animals treated with galantamine behaved as if...
  • Nominal Benefits Seen in Drugs for Alzheimer's

    04/07/2004 10:08:36 PM PDT · by neverdem · 14 replies · 554+ views
    NY TIMES ^ | April 7, 2004 | DENISE GRADY
    The drugs now available to treat the memory and thinking problems of Alzheimer's disease have not lived up to the public's high expectations for them and offer such modest benefits on average that many doctors are unsure about whether to prescribe them. Although the drugs have their advocates, grateful for any sign of improvement, others express disappointment in light of earlier hopes that the drugs approved in the last decade would stop the disease or markedly slow it. At a meeting in late March at Johns Hopkins University, doctors and other health professionals heard Alzheimer's researchers debate the usefulness of...